Friday, July 10, 2026

pharma · wet macula degeneration · Chronic Urticaria

CuraTeQ Biologics s.r.o

CuraTeQ Biologics is a pharma organization headquartered in Hyderabad, IN. Primary therapeutic focus areas include wet macula degeneration, Chronic Urticaria. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s)

Hyderabad, IN HQ
2016 Founded
645 Employees
EMA registrant Type
Company details
Status
Public
HQ
Hyderabad, IN
Founded
2016
Employees
645
Programs
2
Drugs
6
Patents
0
Clinical program

BP11-301

Phase 3 · small molecule · Chronic Urticaria

BP11-301 for Chronic Urticaria is a Phase 3 program (small_molecule) at CuraTeQ Biologics s.r.o with 1 ClinicalTrials.gov record(s).

← All CuraTeQ Biologics s.r.o projects Phase 3 small molecule active

Internal code BP11-301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CuraTeQ Biologics s.r.o
Phase
Phase 3
Modality
small_molecule
Indication
Chronic Urticaria
Status
active
Trials
1